All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 6, 2022
Home » Topics » Regions » Asia-Pacific

Asia-Pacific
Asia-Pacific RSS Feed RSS

03-30-Qure-qremote-mock-up.png

Qure eyes US and Europe expansion for AI imaging diagnostics portfolio

March 30, 2022
By Catherine Longworth
No Comments
Health tech firm Qure.ai Technologies Private Ltd. has secured a $40 million investment from investors including Novo Holdings and Healthquad to expand its portfolio of automated artificial intelligence (AI)-based imaging diagnostics. The company’s suite of technologies incorporates deep learning and AI to interpret radiology images such as X-rays, CTs, and ultrasounds in less than a minute.
Read More
Illustration of pill being analyzed

Elix and Shionogi partner to validate retrosynthetic analysis model to discover drugs

March 30, 2022
By Gina Lee
No Comments
Elix Inc. has teamed up with Shionogi & Co. Ltd. to validate a retrosynthetic analysis model for drug discovery that will employ chemical reaction data from Shionogi to explore various routes to synthesizing new molecules.
Read More
DNA, dollars illustration

Nalagenetics raises $12.6M for preventative care gene testing

March 29, 2022
By David Ho
No Comments
Nalagenetics Pte. Ltd. has landed $12.6 million in a series A round of financing. The Singapore-based company wants to use the capital to expand on its genetic testing solutions to implement predictive and presymptomatic testing for prevention geared towards chronic conditions in Asia.
Read More

Innovent wins sole rights to commercialize two Lilly oncology drugs in $45M deal

March 29, 2022
By Doris Yu
No Comments
Innovent Biologics Inc. has acquired exclusive rights to commercialize Eli Lilly and Co.’s oncology drugs Cyramza (ramucirumab) and Retsevmo (selpercatinib) in mainland China, where it will be responsible for the pricing, importation, marketing, distribution and sales of the two products.
Read More
3d illustration of ovarian cancer

Zai Lab hits primary endpoint in phase III Zejula study for ovarian cancer

March 29, 2022
By Gina Lee
No Comments
Zai Lab Ltd. has shared positive top-line data from its phase III study for PARP inhibitor Zejula (niraparib) in the treatment of newly diagnosed ovarian cancer following a response to platinum-based chemotherapy. The study, called Prime, involved 384 advanced ovarian cancer patients in China and met its primary endpoint.
Read More

Novavax’s COVID-19 vaccine granted EUA for adolescents in India

March 29, 2022
By David Ho
No Comments
The Drugs Controller General of India has granted Novavax Inc. and the Serum Institute of India Pvt. Ltd. emergency use authorization (EUA) for Novavax’s protein-based COVID-19 vaccine. It was authorized for use in adolescents aged 12 to 18 years. The vaccine will be manufactured and marketed in India by the Serum Institute under the brand name Covovax.
Read More
Shanghai, China, stock market illustration

Shouyao Holdings raises $233M in Shanghai IPO

March 29, 2022
By Doris Yu
No Comments
Shouyao Holdings Co. Ltd. raised ¥1.48 billion ($233 million) in a listing on the Shanghai STAR Market to support the company’s ongoing clinical programs, led by a second-generation anaplastic lymphoma kinase inhibitor. Company shares (SHA:688197) debuted at ¥39.90, then fell 19.5% to close at ¥32.11 on March 23.
Read More
Jeong Woo Cho, president and CEO, SK Biopharmaceuticals.

SK Biopharmaceuticals’ three-part epilepsy approach underway

March 29, 2022
By Gina Lee
No Comments
SK Biopharmaceuticals Co. Ltd.'s three-pronged plan for tackling epilepsy is going strong, with lead drug cenobamate for drug-resistant focal-onset seizures nearing the finish line, and earlier-stage programs for a mRNA-based approach and a digital therapeutic in the works.
Read More

Xzing Technology’s disposable endoscope gains NMPA approval

March 28, 2022
By Zhang Mengying
No Comments
Shenzhen Xzing Technology Co. Ltd.’s Endofresh disposable upper gastrointestinal (GI) endoscope has granted the NMPA’s class II approval. The company said the approved product is used for upper gastrointestinal GI endoscopy, diagnosis and treatment.
Read More
Jeong Woo Cho, president and CEO, SK Biopharmaceuticals.

SK Biopharmaceuticals’ three-part epilepsy approach underway

March 25, 2022
By Gina Lee
No Comments
SK Biopharmaceuticals Co. Ltd.'s three-pronged plan for tackling epilepsy is going strong, with lead drug cenobamate for drug-resistant focal-onset seizures nearing the finish line, and earlier-stage programs for a mRNA-based approach and a digital therapeutic in the works.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 … 93 94 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 6, 2022.
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for July 6.
  • Blood sample, DNA

    Biomarin outlines pricing strategy for costly hemophilia A gene therapy after backing from European regulators

    BioWorld
    The first gene therapy to treat severe hemophilia A was among the drugs recommended for European approval by regulators from the EMA’s CHMP at its monthly...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing